ONESOURCEOnesource Specialty Pharma Limited
Pharma · Biotechnology · NSE · as of 2026-09-11 (delayed ~30 min in market hours)
OneSource Specialty Pharma Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biological drug products in various injectable formats in India, Ireland, the United States, and internationally. The company provides end-to-end contract development and manufacturing operations (CDMO) services across various phases of preclinical and clinical development and commercial supply of biologics. It also offers drug-devices, including prefilled syringes, dial and push variable and fixed dose pen injectors, pull push fixed dose pens, and autoinjectors; sterile injectables; soft gelatin capsules; and biologics solutions for microbial and mammalian cell line biopharmaceuticals, cell and gene therapy, and RNA products. The company was formerly known as Stelis Biopharma Limited and changed its name to OneSource Specialty Pharma Limited in February 2024. OneSource Specialty Pharma Limited was incorporated in 2007 and is based in Bengaluru, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
The picture
- • Revenue growth: 37.2% YoY
- • Debt/Equity: 0.26
- • RSI: 55
- • MACD: bullish
- • Price vs EMA21: above
- • 1-month vs NIFTY: +5.4% relative
- • Bollinger Squeeze signal (setup quality 76%)
- • Pullback to 21-EMA signal (setup quality 58%)
Bull case
- • Revenue growth: 37.2% YoY
- • Debt/Equity: 0.26
- • RSI: 55
- • MACD: bullish
Bear case
- • Profit growth: -310.7% YoY
- • ROE: -1.3%
- • Price vs SMA50: below
- • Supertrend: bearish
Key risks
- • Elevated volatility / drawdown profile — size positions accordingly
- • Weak fundamentals — technical strength may not sustain
- • Profit growth: -310.7% YoY
- • ROE: -1.3%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹58.40). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.